In vitro immunomodulatory, antifungal, and antibacterial screening of Phyllanthus niruri against to human pathogenic microorganisms

Background: Medicinal plants present a wide range of potentially phytochemical compounds that contain many useful properties including anticancer, enzyme inhibition, anti-inflammatory, antifungal, antibacterial, immunomodulatory, antioxidant, and antiallergic activities. Phyllanthus niruri capsules are extensively recommended to improve the function of the diseased liver. Its leaves root and the whole plant are used as an herbal complement. Aim: The present study was aimed to focus on the in vitro immunomodulatory activity, antifungal, antibacterial and phytochemical screening of aqueous, methanolic, and ethanolic extract of P. niruri. Materials and Methods: Immunomodulatory activities were evaluated through nitroblue tetrazolium assay. Antifungal and antibacterial activity were conducted against Candida albicans (NCIM - 3100), Aspergillus niger (NCIM - 1028), Eschericha coli (NCIM - 5346), Bacillus subtilis (NCIM - 2920), and Staphylococcus aureus (NCIM - 5345) by using disc diffusion method. Results: Medicinal plants contain polyphenolic compounds which have potent anti-cancer and immunomodulator activity. P. niruri has potential immunomodulatory activity. Aqueous, methanolic, and ethanolic extract of P. niruri did not show any significant antifungal activity and 100 mg/ml, 150 mg/ml, and 200 mg/ml. Aqueous, methanolic, and ethanolic extract showed significant antibacterial activity. Conclusion: From this study, it is concluded that P. niruri does not have antifungal activity but has potent immunomodulatory and antibacterial activity. This immunomodulatory and antibacterial activity of P. niruri may be due to the secondary metabolites such as alkaloid, tannins, terpenoids, flavonoids, and phenol compounds

Not Available

Not AvailableViral nervous necrosis is a serious viral disease of marine and brackishwater finfish hatcheries. The red-spotted grouper nervous necrosis virus (RGNNV) is the most prevalent genotype among fishes in tropical and temperate regions. RGNNV was propagated in SSN-1 cell line and inactivated using BEI. The capsid protein of RGNNV was cloned and expressed in Escherichia coli and purified. Inactivated and recombinant VNN vaccines were produced by emulsifying the antigen with commercial adjuvant and administered to Asian seabass, Lates calcarifer, fingerlings and broodstock intraperitoneally. The immune response was assessed at regular intervals by indirect ELISA. The maternal antibodies in one-day post-hatch larvae obtained from the vaccinated and control broodstock were assessed by indirect ELISA. The larvae were subjected to challenge with virulent RGNNV and the relative per cent survival (RPS) was estimated. The efficacy of the vaccine was also assessed under field conditions. The recombinant vaccine produced significantly higher specific antibody levels than the inactivated vaccine in fingerlings and broodstock and the immune response was dose-dependent. Recombinant vaccine at 50 and 100 μg/fish produced significantly higher antibody levels and immune response could be observed as early as one-week post vaccination. Vaccinated broodstock produced larvae with maternal antibodies and had higher RPS when challenged at 18 days post-hatch. The vaccine produced a significant immune response even under field conditions. The vaccine can be used to vaccinate broodstock to reduce loss due to VNN in early larval stagesNot Availabl